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Community acquired MRSA infections 
a new challenge 
Resistance to methicillin (the first 
beta-lactamase stable penicillin and 
precursor to flu/cloxacillin) was first 
seen amongst hospital isolates of 
Staphylococcus aureus (S. aureus) in 
the early sixties. Since then 
methicillin-resistant S. aureus 
(MRSA) has become widespread in 
hospitals and particularly intensive 
care units around the world . In 
addition, resistance to methicillin has 
extended to other antimicrobial 
groups including macrolides, 
quinolones and aminoglycosides such 
that the term MRSA is also often 
used as an abbreviation for multiply-
resistant S. aureus. MRSA is now one 
of the most common causes of 
bacterial hospital infections, 
accounting for 40 - 70% of the S. 
aureus infections in intensive care 
units. This is particularly the case in 
the local setting where prevalence of 
MRSA is amongst the highest in 
Europe (Figure 1). 
Until some years ago, acquisition 
of MRSA colonisation or infection 
was generally considered to be 
restricted to the nosocomial setting 
and isolates of MRSA from 
individuals in ambulatory care would 
invariably be traced to a previous 
hospitalisation or close contact with 
a recently hospitalised individual. 
However, in the past decade new 
strains of MRSA have emerged in the 
community, causing aggressive 
infections in young, otherwise healthy 
people. Suppurative skin infections 
and less frequently severe necrotising 
pneumonias are the most well-known 
clinical syndromes caused by these 
new strains. 
The ability of new community-
acquired MRSA (CA-MRSA) strains 
to colonise hosts in the community 
and cause clinical syndromes is 
mediated by unique combinations of 
traditional and newly described 
virulence factors. The most weU-
known community-acquired MRSA 
virulence factor is Panton Valentine 
Leucocidin (PVL) , which elicits tissue 
necrosis and may contribute 
substantiaUy to the clinical findings 
in young otherwise healthy 
individuals . CA-MRSA isolates have 
been associated with many of the 
clinical presentations known to occur 
with traditional S. aureus infection. 
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Winning with TheSYNAPSE 
TheSYNAPSE Internet Portal has, for the past few months, been publishing a number of eQUIZes for Maltese Medical Doctors. 
We are pleased to publish the winners of the eQUIZes for the first Quarter of 2006. 
Company Product Winner 
Sanofi Aventis Telfast Dr Michael A. Borg 
Sanofi Aventis Ketek Dr Tania Van Avendonk 
Sanofi Aventis Tavanic Dr Mary Rose Cassar 
Bayer Avalox Dr Alex Magri 
Actavis Tirabicin Dr Doreen Cassar 
Lundbeck Cipralex Dr Tonio Bugeja 
Sanofi Aventis Rhinatiol Dr Julian Mamo 
There are lots of other planned eQUIZes and other opportunities planned for the coming months and you could be one of 
the winners . Be sure you are eligible to participate by making sure you are a member ofTheSYNAPSE internet community and 
receive your weekly eNEWS . If you have any queries please contact our helpdesk by email onhelpdesk@thesynapse.net . 
Note 
Part II of the series Cardiology Today by Prof. 
Albert Fenech will be featured in the next issue 
of TheSYNAPSE magazine and not in this 
issue as previously announced. 
Errata ... 
A number of articles in the 
November 2005 Issue were 
published without the list of 
references. All references will now 
appear in the on line version of 
the magazine which is being 
published. We apo logise to the 
authors and audience for the 
inconvenience. 
